Literature DB >> 29417621

Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience.

Inuk Zandvakili1, Caitlin B Conboy1,2, Ayed O Ayed2, Elizabeth J Cathcart-Rake2, Ayalew Tefferi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29417621     DOI： 10.1002/ajh.25063

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  14 in total

1.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

2.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

3.  Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Scott R Goldsmith; Sana Saif Ur Rehman; Cara L Shirai; Kiran Vij; John F DiPersio
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

5.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

6.  Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.

Authors:  Adriana A de Jesus; Yangfeng Hou; Stephen Brooks; Louise Malle; Angelique Biancotto; Yan Huang; Katherine R Calvo; Bernadette Marrero; Susan Moir; Andrew J Oler; Zuoming Deng; Gina A Montealegre Sanchez; Amina Ahmed; Eric Allenspach; Bita Arabshahi; Edward Behrens; Susanne Benseler; Liliana Bezrodnik; Sharon Bout-Tabaku; AnneMarie C Brescia; Diane Brown; Jon M Burnham; Maria Soledad Caldirola; Ruy Carrasco; Alice Y Chan; Rolando Cimaz; Paul Dancey; Jason Dare; Marietta DeGuzman; Victoria Dimitriades; Ian Ferguson; Polly Ferguson; Laura Finn; Marco Gattorno; Alexei A Grom; Eric P Hanson; Philip J Hashkes; Christian M Hedrich; Ronit Herzog; Gerd Horneff; Rita Jerath; Elizabeth Kessler; Hanna Kim; Daniel J Kingsbury; Ronald M Laxer; Pui Y Lee; Min Ae Lee-Kirsch; Laura Lewandowski; Suzanne Li; Vibke Lilleby; Vafa Mammadova; Lakshmi N Moorthy; Gulnara Nasrullayeva; Kathleen M O'Neil; Karen Onel; Seza Ozen; Nancy Pan; Pascal Pillet; Daniela Gp Piotto; Marilynn G Punaro; Andreas Reiff; Adam Reinhardt; Lisa G Rider; Rafael Rivas-Chacon; Tova Ronis; Angela Rösen-Wolff; Johannes Roth; Natasha Mckerran Ruth; Marite Rygg; Heinrike Schmeling; Grant Schulert; Christiaan Scott; Gisella Seminario; Andrew Shulman; Vidya Sivaraman; Mary Beth Son; Yuriy Stepanovskiy; Elizabeth Stringer; Sara Taber; Maria Teresa Terreri; Cynthia Tifft; Troy Torgerson; Laura Tosi; Annet Van Royen-Kerkhof; Theresa Wampler Muskardin; Scott W Canna; Raphaela Goldbach-Mansky
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 7.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Authors:  Mounica Vallurupalli; Nancy Berliner
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

8.  A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.

Authors:  Qing Zhang; Ang Wei; Hong-Hao Ma; Li Zhang; Hong-Yun Lian; Dong Wang; Yun-Ze Zhao; Lei Cui; Wei-Jing Li; Ying Yang; Tian-You Wang; Zhi-Gang Li; Rui Zhang
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

9.  Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib.

Authors:  Ramy M Hanna; Maham Khalid; Lama Abd El-Nour; Umut Selamet
Journal:  Antibiotics (Basel)       Date:  2019-09-16

Review 10.  The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.

Authors:  Alice Wang; Katelyn Singh; Wael Ibrahim; Brett King; William Damsky
Journal:  Yale J Biol Med       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.